Argenica Therapeutics Limited (ASX:AGN)

Australia flag Australia · Delayed Price · Currency is AUD
0.205
+0.005 (2.50%)
Mar 10, 2026, 11:23 AM AEST
-73.38%
Market Cap 25.69M
Revenue (ttm) 1.01M
Net Income (ttm) -9.80M
Shares Out 128.46M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 229,796
Average Volume 113,472
Open 0.200
Previous Close 0.200
Day's Range 0.200 - 0.210
52-Week Range 0.190 - 0.860
Beta 0.60
RSI 33.95
Earnings Date Feb 10, 2026

About Argenica Therapeutics

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol AGN
Full Company Profile

Financial Performance

In fiscal year 2025, Argenica Therapeutics's revenue was 3.21 million, an increase of 23.70% compared to the previous year's 2.60 million. Losses were -7.17 million, 30.9% more than in 2024.

Financial Statements

News

There is no news available yet.